THYME AND CARVACROLL Nanoparticle Effect on Fungi
Sponsor
Assiut University (Other)
Overall Status
Completed
CT.gov ID
NCT04431804
Collaborator
(none)
210
1
3.6
57.6
Study Details
Study Description
Brief Summary
Invasive Aspergillosis (IA) has increasingly been recognized as an emerging disease of non-neutropenic patients and in patients admitted to the ICU, even in the absence of an apparent predisposing immune-deficiency, with incidence ranges from 0.3% to 5.8% with an overall mortality rate exceeding 80%.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
210 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Effect of Thyme and Carvacroll Nanoparticles on Aspergillus Fumigatus Isolate From Intensive Care Patients
Actual Study Start Date
:
Jun 11, 2020
Actual Primary Completion Date
:
Sep 20, 2020
Actual Study Completion Date
:
Sep 30, 2020
Outcome Measures
Primary Outcome Measures
- fungicidal effect of silver nanoparticles on aspergillus fumigatus [24 hours]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
- intensive care patients
Exclusion Criteria:
- none
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Assiut university | Assiut | Egypt | 71111 |
Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Rasha Hamed,
lecturer of anaesthesia,
Assiut University
ClinicalTrials.gov Identifier:
NCT04431804
Other Study ID Numbers:
- wwww
First Posted:
Jun 16, 2020
Last Update Posted:
Nov 5, 2020
Last Verified:
Nov 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: